Ocular Therapeutix™ Reports Positive Topline Clinical Data for the First of Two Phase 3 Clinical Trials Evaluating OTX-DP for the Treatment of Post-Surgical Ocular Inflammation and Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
| (NASDAQ: OCUL) | Delayed: 6.61 +0.13 (2.01%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.48 | 52 Week High | $14.50 | |||
| Open | $6.42 | 52 Week Low | $4.04 | |||
| Day High | $6.67 | P/E | N/A | |||
| Day Low | $6.40 | EPS | $0.00 | |||
| Volume | 2,145,013 | |||||
